Information  X 
Enter a valid email address

Syncona Limited (SYNC)

  Print      Mail a friend

Wednesday 20 May, 2020

Syncona Limited

Notice of Results

RNS Number : 4768N
Syncona Limited
20 May 2020
 

 

 

 

Syncona Limited

 

Notice of Final Results

 

20 May 2020

 

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, will announce its final results for the year ended 31 March 2020 on Thursday 11 June 2020.

 

Syncona will publish a pre-record presentation at 7.00 am BST, followed by a Q&A session accessible via conference call or webcast at 9.30am BST. The webcast will be available on the Company's website at https://www.synconaltd.com/ or Webcast Link. Alternatively, please contact [email protected] for details of the conference call.

 

[ENDS]

 

Enquiries

 

Syncona Ltd

Siobhan Weaver / Annabel Clay 

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

 

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORKKKBDFBKKCPB

a d v e r t i s e m e n t